eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Short Interest Up 650.0% in June

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 687,000 shares, an increase of 650.0% from the June 15th total of 91,600 shares. Based on an average daily trading volume, of 645,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 16.8% of the company’s shares are sold short.

eFFECTOR Therapeutics Stock Up 19.6 %

eFFECTOR Therapeutics stock traded up $0.01 during mid-day trading on Friday, hitting $0.08. 101,046 shares of the stock were exchanged, compared to its average volume of 480,155. eFFECTOR Therapeutics has a 12 month low of $0.03 and a 12 month high of $21.50. The firm’s fifty day simple moving average is $1.24 and its two-hundred day simple moving average is $6.87. The stock has a market capitalization of $376,470.00, a price-to-earnings ratio of 0.00 and a beta of 0.62.

eFFECTOR Therapeutics (NASDAQ:EFTR) last released its quarterly earnings results on Thursday, May 9th. The company reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.17) by $0.01. As a group, analysts forecast that eFFECTOR Therapeutics will post -5.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $24.00 price objective on shares of eFFECTOR Therapeutics in a report on Thursday, March 28th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in eFFECTOR Therapeutics stock. StemPoint Capital LP purchased a new position in shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 132,793 shares of the company’s stock, valued at approximately $1,911,000. StemPoint Capital LP owned about 3.60% of eFFECTOR Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 57.67% of the company’s stock.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.